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Introduction
Remifentanil target-controlled infusion (TCI), widely
used in the operating room owing to its reliability, is
poorly assessed in the ICU, while several procedures
may induce pain and discomfort. Only one series of 14
patients focused on Remifentanil-TCI use for perform-
ing fiberoptic bronchoscopy (FB) in the ICU [1]. We
aimed to assess Remifentanil-TCI feasibility, safety and
tolerance during FB performed in consecutive non-intu-
bated ICU patients.
Objectives
Primary end point was FB complete achievement, with
Remifentanil TCI and standardized local anesthesia with-
out need for general anaesthesia or additional analgesia.
Secondary aims were objective (respiratory and hemody-
namics parameters) and subjective (pain, dyspnea and
comfort assessment) tolerance and safety measurements
during and after the procedure.
Methods
Observational prospective study of Remifentanil target-
controlled infusion (TCI) use during FB performed in
non-intubated ICU patients. Quantitative and qualitative
variables are presented as median [interquartile range]
and number (percentage), respectively.
Results
From November 2014 to March 2015, 40 patients (age
59 yrs [41-71], 75% men; SAPS II score 28 [22-39])
were included. FB was performed in patients receiving
nasal oxygen (85%), high-flow humidified oxygen
(12.5%) or non-invasive ventilation (2.5%), and a
broncho-alveolar lavage was done in 7 patients (17.5%).
Total infusion duration was 22 minutes [15-29], TCI
concentration goal was 4 ng/mL [3.5-5.5] and total drug
dose infused wad 279 µg [196-377].
FB was performed completely without any additional
drugs in 38 patients (95%), whereas propofol was used in
2 (5%). Three patients presented side effects comprising
bradypnea (n = 1) and hypotension (systolic arterial pres-
sure of 70 mmHg, n = 2) that occurred during the proce-
dure and were completely reversible with TCI goal
decrease. Thus, FB was performed entirely without addi-
tional anesthesia or complication in 35 patients (87.5%).
Comfort was assessed in 28 patients (70%): 22 (79%)
stated that they experienced a bearable pain or no pain
at all, 6 (21%) had a moderate pain, and none felt severe
pain. Among the 26 patients who were asked, 20 (77%)
would agree to have a FB in the same conditions.
Conclusions
Our findings suggest that TCI of Remifentanil may be
useful and safe, for performing FB in the ICU, with
acceptable patients’ comfort and tolerance, even in those
with respiratory failure. The study completion should
strengthen these preliminary results.
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